NCT03092323: Phase 2: (SU2C-SARC032) - A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
- CTD
- Jun 29, 2024
- 1 min read
First Posted | 2017-03-27 |
Trial status | Active, not recruiting |
Sponsor | Sarcoma Alliance for Research through Collaboration |
Abstract Presentation | Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.
|
Peer-reviewed journal publication | THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
|
Press Release | SU2C-SARC032 Positive Results Revealed at ASCO June 7, 2024 Meeting Abstract: 2024 ASCO Annual Meeting I Free access Sarcoma May 29, 2024
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. |
FDA | |
NCCN |
NCT03092323: Phase 2: (SU2C-SARC032) - A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
(A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)
Official Title: |
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity |
Intervention / Treatment: |
Drug: Pembrolizumab |
Other Study ID Numbers: |
SU2C-SARC032 |
ClinicalTrials.gov Link: https://www.clinicaltrials.gov/study/NCT03092323 |